Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues.

Literature DB >> 389810

The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues.

Abstract

In this review the pharmacokinetic properties of trimethoprim (TMP) and TMP/sulphonamide combinations are discussed. The concentration of both substances in the various body fluids and tissues differ considerably from the concentrations in blood due to the different distribution of TMP and sulphonamides in the body. As a rule the ratio of the concentration of TMP to sulphonamide is higher in most body fluids and secretions than in blood. If inflammation is present, the concentrations vary considerably. The pharmacokinetic data must be taken into account when making in vitro tests. At the site of inflammation a TMP/sulphonamide concentration factor of 1:0.5 to 1:4 can be expected in urine and of 1:2 to 1:5 in tissue.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1979 PMID： 389810 DOI： 10.1007/bf01639009

Source DB: PubMed Journal: Infection ISSN： 0300-8126 Impact factor: 3.553

66 in total

1. The permeability of the human parotid gland to a series of sulfonamide compounds, para-aminohippurate and inulin.

Authors: S A KILLMANN; J H THAYSEN
Journal: Scand J Clin Lab Invest Date: 1955 Impact factor: 1.713

2. Kinetics of a sulfadiazine-trimethoprim combination.

Authors: T Bergan; H Vik-Mo; U Anstad
Journal: Clin Pharmacol Ther Date: 1977-08 Impact factor: 6.875

3. Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects.

Authors: P Männistö; J Tuomisto; N E Saris; T Lehtinen
Journal: Chemotherapy Date: 1973 Impact factor: 2.544

4. Studies on the physiological availability and metabolism of sulfonamides. I. Sulfadiazine.

Authors: G R Van Petten; G C Becking; R J Withey; H F Lettau
Journal: J Clin Pharmacol New Drugs Date: 1971 Jan-Feb

5. Kidney transport in man of sulfamethoxazole and trimethoprim.

Authors: T Bergan; E K Brodwall
Journal: Chemotherapy Date: 1972 Impact factor: 2.544

6. Comparative study of Gantanol in serum and prostatic tissue.

Authors: S Kumar; G W Jones
Journal: J Natl Med Assoc Date: 1973-01 Impact factor: 1.798

7. Metabolism and techniques for assay of trimethoprim and sulfamethoxazole.

Authors: J Rieder
Journal: J Infect Dis Date: 1973-11 Impact factor: 5.226

8. Trimethoprim, a sulphonamide potentiator.

Authors: S R Bushby; G H Hitchings
Journal: Br J Pharmacol Chemother Date: 1968-05

9. Treatment of meningitis and septicemia in infancy with a sulphamethoxazole/trimethorpim combination.

Authors: K G Sabel; A Brandberg
Journal: Acta Paediatr Scand Date: 1975-01

10. Trimethoprim in normal and pathological human lung tissue.

Authors: I Hansen; M Lykkegaard Nielsen; L Heerfordt; B Henriksen; S Bertelsen
Journal: Chemotherapy Date: 1973-10 Impact factor: 2.544

21 in total

Review 1. Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors: Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal: Adv Drug Deliv Rev Date: 2011-12-21 Impact factor: 15.470

2. Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.

Authors: Claire Pressiat; Veronique Mea-Assande; Caroline Yonaba; Jean-Marc Treluyer; Désiré-Lucien Dahourou; Madeleine Amorissani-Folquet; Stéphane Blanche; François Eboua; Diarra Ye; Gabrielle Lui; Karen Malateste; Yi Zheng; Valeriane Leroy; Déborah Hirt
Journal: Br J Clin Pharmacol Date: 2017-09-20 Impact factor: 4.335

3. Trimethoprim/sulphonamide: concluding remarks.

Authors: W Marget
Journal: Infection Date: 1979 Impact factor: 3.553

4. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.

Authors: Nader Baharivand; Ali Mahdavifard; Rohollah Fadaei Fouladi
Journal: Int Ophthalmol Date: 2012-09-28 Impact factor: 2.031

5. Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.

Authors: I D Watson; H N Cohen; M J Stewart; S J McIntosh; A Shenkin; J A Thomson
Journal: Br J Clin Pharmacol Date: 1982-09 Impact factor: 4.335

6. The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.

Authors: Katelyn R Keyloun; Molly C Reid; Ryan Choi; Yifan Song; Anna M W Fox; Heidi K Hillesland; Zhongsheng Zhang; RamaSubbaRao Vidadala; Ethan A Merritt; Audrey O T Lau; Dustin J Maly; Erkang Fan; Lynn K Barrett; Wesley C Van Voorhis; Kayode K Ojo
Journal: Parasitology Date: 2014-06-13 Impact factor: 3.234

Review 7. Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors: R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal: Drugs Date: 1982-06 Impact factor: 9.546

8. Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors: Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal: Antimicrob Agents Chemother Date: 2009-07-20 Impact factor: 5.191

9. Age-related alterations in trimethoprim-sulfadiazine disposition following oral or parenteral administration in calves.

Authors: C L Guard; W S Schwark; D S Friedman; P Blackshear; M Haluska
Journal: Can J Vet Res Date: 1986-07 Impact factor: 1.310

10. Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine.

Authors: C Astbury; J Hill; H A Bird
Journal: Ann Rheum Dis Date: 1988-04 Impact factor: 19.103